This database contains 125 studies, archived under the term: "Alzheimer"
Click here to filter this large number of results.
Comparing the efficacy and safety of Crocus sativus L. With memantine in patients with moderate to severe Alzheimer’s disease: A double‐blind randomized clinical trial
Farokhnia, Mehdi,
Shafiee Sabet, Mehdi,
Iranpour, Negar,
Gougol, Amirhossein,
Yekehtaz, Habibeh,
Alimardani, Roozbeh,
Farsad, Farzaneh,
Kamalipour, Maryam,
Akhondzadeh, Shahin
Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]
Learning in Alzheimer’s disease is facilitated by social interaction
Seminal work in Gary Van Hoesen’s laboratory at Iowa in the early 1980s established that the hallmark neuropathology of Alzheimer’s disease (AD; neurofibrillary tangles) had its first foothold in specific parts of the hippocampal formation and entorhinal cortex, effectively isolating the hippocampus from much of its input and output and causing the distinctive impairment of […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]
The effect of souvenaid on functional brain network organisation in patients with mild Alzheimer’s disease: a randomised controlled study
de Waal, Hanneke,
Stam, Cornelis J.,
Lansbergen, Marieke M.,
Wieggers, Rico L.,
Kamphuis, Patrick J. G. H.,
Scheltens, Philip,
Maestú, Fernando,
van Straaten, Elisabeth C. W.
Background: Synaptic loss is a major hallmark of Alzheimer’s disease (AD). Disturbed organisation of large-scale functional brain networks in AD might reflect synaptic loss and disrupted neuronal communication. The medical food Souvenaid, containing the specific nutrient combination Fortasyn Connect, is designed to enhance synapse formation and function and has been shown to improve memory performance […]
Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease
Davenward, Samantha,
Bentham, Peter,
Wright, Jan,
Crome, Peter,
Job, Deborah,
Polwart, Anthony,
Exley, Christopher
There has been a plausible link between human exposure to aluminum and Alzheimer’s disease for several decades. We contend that the only direct and ethically acceptable experimental test of the ‘aluminum hypothesis’, which would provide unequivocal data specific to the link, is to test the null hypothesis that a reduction in the body burden of […]
Neuromidin in mixed vascular and Alzheimer’s dementia
The efficacy of neuromidin (ipidacrinum), a nonselective inhibitor of acetylcholinesterase and butyrilcholinesterase was studied in patients with mixed vascular and Alzheimer’s dementia of mild and moderate severity. Thirty patients of the main group received neyromidin in dosage 80 mg/day during 3 months; 10 patients of the comparison group matched by age, sex and severity of […]